Camp4 Therapeutics Corporation (CAMP)
NASDAQ: CAMP · Real-Time Price · USD
6.49
+0.48 (7.99%)
At close: Dec 12, 2025, 4:00 PM EST
6.36
-0.13 (-2.02%)
After-hours: Dec 12, 2025, 6:50 PM EST
Camp4 Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts that cover Camp4 Therapeutics stock have a consensus rating of "Buy" and an average price target of $9.00, which forecasts a 38.67% increase in the stock price over the next year. The lowest target is $7.00 and the highest is $12.
Price Target: $9.00 (+38.67%)
Analyst Consensus: Buy
* Price targets were last updated on Oct 2, 2025.
Analyst Ratings
The average analyst rating for Camp4 Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 5 | 5 | 5 | 6 | 6 | 3 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 7 | 7 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $7 | Buy | Initiates | $7 | +7.86% | Oct 2, 2025 |
| JP Morgan | JP Morgan | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Sep 16, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $18 → $12 | Buy | Maintains | $18 → $12 | +84.90% | Sep 15, 2025 |
| Wedbush | Wedbush | Buy Initiates $8 | Buy | Initiates | $8 | +23.27% | May 27, 2025 |
| William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Nov 5, 2024 |
Financial Forecast
Revenue This Year
3.46M
from 652.00K
Increased by 430.67%
Revenue Next Year
629.00K
from 3.46M
Decreased by -81.82%
EPS This Year
-1.88
from -11.04
EPS Next Year
-1.02
from -1.88
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 3.9M | 2.6M | ||||
| Avg | 3.5M | 629,003 | ||||
| Low | 2.9M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 504.0% | -24.1% | ||||
| Avg | 430.7% | -81.8% | ||||
| Low | 350.9% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.33 | -0.83 | ||||
| Avg | -1.88 | -1.02 | ||||
| Low | -2.26 | -1.20 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.